Kaufman MR, Goldman HB, Chermansky CJ, Dmochowski R, Kennelly MJ, Peters KM, Quiroz LH, Bennett JB, Thomas S, Marguet CG, Benson KD, Lee UJ, Sokol ER, Wolter CE, Katz DM, Tarnay CM, Antosh D, Heit MH, Rehme C, Karram M, Snyder S, Canestrari E, Jankowski RJ, Chancellor MB. Iltamiocel Autologous Cell Therapy for the Treatment of Female Stress Urinary Incontinence: A Double-Blind, Randomized, Stratified, Placebo-Controlled Trial. Neurourol Urodyn. 2024 Sep 16. doi: 10.1002/nau.25588.
Knowles CH, Canestrari E, Jankowski RJ, Cardello K, Raval MJ. Safety and Efficacy of Iltamiocel Cellular Therapy for the Treatment of Fecal Incontinence. Results of a Phase 1/2 Study. Ann Surg. 2023 Dec 1;278(6):937-944.
Nativ-Zeltzer N, Kuhn MA, Evangelista L, Anderson JD, Nolta JA, Farwell DG, Canestrari E, Jankowski RJ, Belafsky PC. Autologous Muscle-Derived Cell Therapy for Swallowing Impairment in Patients Following Treatment for Head and Neck Cancer. Laryngoscope. 2022 Mar;132(3):523-527. doi: 10.1002/lary.29606.
Gilleran J, Diokno AC, Ward E, Sirls L, Hasenau D, Giordano J, Shea E, Bartolone SN, Lamb LE, Chancellor MB. Improved global response outcome after intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder. Int Urol Nephrol. 2021 Jul;53(7):1331-1338. doi: 10.1007/s11255-021-02847-1.
Jankowski RJ, Tu LM, Carlson C, et al. A double-blind, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of autologous muscle derived cells in female subjects with stress urinary incontinence. Int Urol Nephrol. 2018;50(12):2153-2165. doi:10.1007/s11255-018-2005-8
Chancellor MB, Bartolone SN, DeVries EM, et al. New technology assessment and current and upcoming therapies for underactive bladder. Neurourol Urodyn. 2018;37(8):2932-2937. doi:10.1002/nau.23738
Peters KM, Dmochowski RR, Carr LK, et al. Autologous muscle derived cells for treatment of stress urinary incontinence in women. J Urol. 2014;192(2):469-476. doi:10.1016/j.juro.2014.02.047
Carr LK, Robert M, Kultgen PL, et al. Autologous muscle derived cell therapy for stress urinary incontinence: a prospective, dose ranging study. J Urol. 2013;189(2):595-601. doi:10.1016/j.juro.2012.09.028
Carr LK, Steele D, Steele S, et al. 1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(6):881-883. doi:10.1007/s00192-007-0553-z